Cargando…

Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a pho...

Descripción completa

Detalles Bibliográficos
Autores principales: Palzer, Julian, Mues, Benedikt, Goerg, Richard, Aberle, Merel, Rensen, Sander S, Olde Damink, Steven W M, Vaes, Rianne D W, Cramer, Thorsten, Schmitz-Rode, Thomas, Neumann, Ulf P, Slabu, Ioana, Roeth, Anjali A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079353/
https://www.ncbi.nlm.nih.gov/pubmed/33935496
http://dx.doi.org/10.2147/IJN.S288379
_version_ 1783685210259324928
author Palzer, Julian
Mues, Benedikt
Goerg, Richard
Aberle, Merel
Rensen, Sander S
Olde Damink, Steven W M
Vaes, Rianne D W
Cramer, Thorsten
Schmitz-Rode, Thomas
Neumann, Ulf P
Slabu, Ioana
Roeth, Anjali A
author_facet Palzer, Julian
Mues, Benedikt
Goerg, Richard
Aberle, Merel
Rensen, Sander S
Olde Damink, Steven W M
Vaes, Rianne D W
Cramer, Thorsten
Schmitz-Rode, Thomas
Neumann, Ulf P
Slabu, Ioana
Roeth, Anjali A
author_sort Palzer, Julian
collection PubMed
description INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. MATERIAL AND METHODS: ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40–47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. RESULTS: Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 µg(Fe)/mL and 225 µg(Fe)/mL, respectively. ML at a concentration of 225 µg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. CONCLUSION: Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations.
format Online
Article
Text
id pubmed-8079353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80793532021-04-29 Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids Palzer, Julian Mues, Benedikt Goerg, Richard Aberle, Merel Rensen, Sander S Olde Damink, Steven W M Vaes, Rianne D W Cramer, Thorsten Schmitz-Rode, Thomas Neumann, Ulf P Slabu, Ioana Roeth, Anjali A Int J Nanomedicine Original Research INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. MATERIAL AND METHODS: ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40–47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. RESULTS: Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 µg(Fe)/mL and 225 µg(Fe)/mL, respectively. ML at a concentration of 225 µg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. CONCLUSION: Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations. Dove 2021-04-23 /pmc/articles/PMC8079353/ /pubmed/33935496 http://dx.doi.org/10.2147/IJN.S288379 Text en © 2021 Palzer et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Palzer, Julian
Mues, Benedikt
Goerg, Richard
Aberle, Merel
Rensen, Sander S
Olde Damink, Steven W M
Vaes, Rianne D W
Cramer, Thorsten
Schmitz-Rode, Thomas
Neumann, Ulf P
Slabu, Ioana
Roeth, Anjali A
Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title_full Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title_fullStr Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title_full_unstemmed Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title_short Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
title_sort magnetic fluid hyperthermia as treatment option for pancreatic cancer cells and pancreatic cancer organoids
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079353/
https://www.ncbi.nlm.nih.gov/pubmed/33935496
http://dx.doi.org/10.2147/IJN.S288379
work_keys_str_mv AT palzerjulian magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT muesbenedikt magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT goergrichard magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT aberlemerel magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT rensensanders magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT oldedaminkstevenwm magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT vaesriannedw magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT cramerthorsten magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT schmitzrodethomas magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT neumannulfp magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT slabuioana magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids
AT roethanjalia magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids